Accueil
Explorer
nav.journalClub
Tendances
Plus
synapse
⌘+K
Langue
Français
JAAD CME Part 2: Clinical Evidence and Safety Considerations for GLP-1 Receptor Agonists in Dermatology | Synapse
March 3, 2026
JAAD CME Part 2: Clinical Evidence and Safety Considerations for GLP-1 Receptor Agonists in Dermatology
SN
Shanthi Narla
RN
Radhika Narla
VA Puget Sound Health Care System
Key Points
Clinical evidence demonstrates the effectiveness of GLP-1 receptor agonists in treating dermatological conditions, enhancing patient outcomes.
Safety considerations for these interventions reveal minimal adverse effects, making them a viable option for treatment.
Analysis focuses on the applications of GLP-1 receptor agonists, examining their benefits in managing skin disorders effectively.
Overall, findings indicate the need for further exploration of these therapies in broader dermatological contexts.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Narla et al. (Sun,) studied this question.
synapsesocial.com/papers/69a76115c6e9836116a2ea77
https://doi.org/https://doi.org/10.1016/j.jaad.2025.12.116